Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice

Cancer Research

Volumn 65, Issue 17, 2005, Pages 7644-7652

  Park, Sung Sup ^a,b   Shaffer, Arthur L ^a   Kim, Joong Su ^a,b   DuBois, Wendy ^a   Potter, Michael ^a   Staudt, Louis M ^a   Janz, Siegfried ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HISTIDINE; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 6;

5' UNTRANSLATED REGION; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA MICROARRAY; ENHANCER REGION; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE INSERTION; GENE LOCUS; GENE OVEREXPRESSION; GENE SEGREGATION; GENE TARGETING; GENE TRANSFER; GENETIC SUSCEPTIBILITY; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; INTESTINE LYMPHATIC TISSUE; INTRON; MOUSE; NONHUMAN; ONCOGENE MYC; PERITONEAL PLASMACYTOMA; PERITONEUM CANCER; PLASMACYTOMA; PRIORITY JOURNAL; TRANSGENE; TRANSGENIC MOUSE;

ALLELES; ANIMALS; GENE EXPRESSION; GENES, IMMUNOGLOBULIN; GENES, MYC; LYMPHOID TISSUE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PERITONEAL NEOPLASMS; PLASMACYTOMA; PRECANCEROUS CONDITIONS; TRANSGENES;

EID: 24744440161     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1222     Document Type: Article

References (51)

1. Potter M. Neoplastic development in plasma cells, Immunol Rev 2003;194:177-95.
2. Potter M, Pumphrey JG, Bailey DW. Genetics of susceptibility to plasmacytoma induction. I. BALB/cAnN (C), C57BL/6N (B6), C57BL/Ka (BK), (C times B6)F1, (C times BK)F1, and C times B recombinant-inbred strains. J Natl Cancer Inst 1975;54:1413-7.
3. Zhang SL, DuBois W, Ramsay ES. et al. Efficiency alleles of the pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol 2001;21:310-8.
4. Bliskovsky V, Ramsay ES, Scott J, et al. Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc Natl Acad Sci U S A 2003;100:14982-7.
5. Anderson PN, Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature 1969;222:994-5.
6. Potter M, MacCardle RC. Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice. J Natl Cancer Inst 1964;33:497.
7. Shacter E, Arzadon GK, Williams J. Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. Blood 1992;80:194-202.
8. Lattanzio G, Libert C, Aquilina M, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997;151:689-96.
9. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002;2:945-56.
10. Byrd LG, McDonald AH, Gold LG, Potter M. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane. J Immunol 1991;147:3632-7.
11. McIntire KR, Princler GL. Prolonged adjuvant stimulation in germ-free BALB-c mice: development of plasma cell neoplasia. Immunology 1969;17:481-7.
12. Shen-Ong GL, Keath EJ, Piccoli SP, Cole MD. Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. Cell 1982;31:443-52.
13. Kovalchuk AL, Kim JS, Park SS, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A 2002;99:1509-14.
14. Silva S, Kovalchuk AL, Kim JS, Klein G, Janz S. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. Cancer Res 2003;63:8656-63.
15. Park SS, Kim JS, Tessarollo L, et al. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 2005;65:1306-15.
16. Morse HC III, Anver MR, Fredrickson TN, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002;100:246-58.
17. Shaffer AL, Yu X, He Y, et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
18. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004;21:81-93.
19. Zhang S, Ramsay ES, Mock BA. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p161NK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc Natl Acad Sci U S A 1998;95:2429-34.
20. Potter M, Wax JS. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J Natl Cancer Inst 1983;71:391-5.
21. Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A 1996;93:4885-90.
22. Potter M, Mushinski EB, Wax JS, Hartley J, Mock BA. Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice. Cancer Res 1994;54:969-75.
23. Alizadeh A, Eisen M, Davis RE, et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999;64:71-8.
24. Shaffer AL, Rosenwald A. Hurt EM, et al. Signatures of the immune response. Immunity 2001;15:375-85.
25. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J Jr. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003;102:592-600.
26. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002;17:51-62.
27. Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression, Genes Dev 2002;16:2530-43.
28. Smith AJ, De Sousa MA, Kwabi-Addo B, et al. A site-directed chromosomal translocation induced in embryonic stem cells by Cre-loxP recombination. Nat Genet 1995;9:376-85.
29. Clynes R, Wax J, Stanton LW, et al. Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-m/c/v-Ha-ras retrovirus. Proc Natl Acad Sci U S A 1988;85:6067-71.
30. Potter M, Mushinski JF, Mushinski EB, et al. Avian v-myc replaces chromosomal translocation in murine plasmacytomagenesis. Science 1987;235:787-9.
31. Troppmair J, Potter M, Wax JS, Rapp UR. An altered v-raf is required in addition to v-myc in J3V1 virus for acceleration of murine plasmacytomagenesis. Proc Natl Acad Sci U S A 1989;86:9941-5.
32. Largaespada DA, Kaehler DA, Mishak H, et al. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. Oncogene 1992;7:811-9.
33. Weissinger EM, Byrd LG, Henderson DW, Mushinski JF. Overexpression of v-abl uniquely cooperates with c-myc dysregulation in induction of plasma cell tumors, bypassing the need for T-lymphocytic help and overcoming T-lymphocytic interference. Int J Cancer 1996;67:142-7.
34. Tahara M, Pergolizzi RG. Kobayashi H, et al. Transsplicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-lgM X-linked immunodeficiency. Nat Med 2004;10:835-41.
35. Byrd L, Potter M. Mock B, Huppi K. The effect of the nude gene on plasmacytoma development in BALB/cAn mice. Curr Top Microbiol Immunol 1988;137:268-75.
36. Adams JM, Harris AW. Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nature 1985;318:533-8.
37. Suda Y, Aizawa S, Hirai S, et al. Driven by the same Ig enhancer and SV40 T promoter ras induced lung adenomatous tumors, myc induced pre-B cell lymphomas and SV40 large T gene a variety of tumors in transgenic mice, EMBO J 1987;6:4055-65.
38. Schmidt EV, Pattengale PK, Weir L, Leder P. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model. Proc Natl Acad Sci U S A 1988;85:6047-51.
39. Butzler C, Zou X, Popov AV, Bruggemann M. Rapid induction of B-cell lymphomas in mice carrying a human IgH/c-mycYAC. Oncogene 1997;14:1383-8.
40. Palomo C, Zou X, Nicholson IC, Butzler C, Bruggemann M. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu). Cancer Res 1999;59:5625-8.
41. Kovalchuk AL, Qi CF, Torrey TA, et al. Burkitt lymphoma in the mouse. J Exp Med 2000;192:1183-90.
42. Rosenbaum H, Harris AW, Bath ML, et al. An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J 1990;9:897-905.
43. Janz S, Potter M, Rabkin CS. Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer 2003;36:211-23.
44. Janz S, Müller J, Shaughnessy J, Potter M. Detection of recombinations between c-myc and immunoglobulin switch α in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. Proc Natl Acad Sci U S A 1993;90:7361-5.
45. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003;22:9007-21.
46. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
47. Weber A, Liu J, Collins I, Levens D. TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression. Mol Cell Biol 2005;25:147-61.
48. Levens DL. Reconstructing MYC. Genes Dev 2003;17:1071-7.
49. Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-7.
50. Lee AH. Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003;100:9946-51.
51. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997;276:596-9.